What’s Hot at AACR 2016? Annual Meeting Preview 1
The 2016 annual meeting of the American Association for Cancer Research (AACR) takes place next month in New Orleans. (Twitter #AACR16).
While many people have focused on the presentation of clinical data at ASCO, we have long argued that emerging scientific data at AACR actually give early hint of what’s to come down the pipeline.
Anticipating these trends and spotting promising new compounds or combinations is probably more art than science, but nonetheless is a very useful and important exercise.
AACR is the most important meeting of the year for cancer new product development!
Tomorrow, we will be reviewing the actual abstracts, posters, late breakers and what they entail, including important new data such as BMS’s CheckMate–141 exploring nivolumab in Head & Neck cancer as well as the combination of nivolumab plus ipilimumab in CheckMate–069 for advanced melanoma.
In the meantime, what are the main hot topics emerging from this year’s meeting in targeted therapies and immunotherapies? What do the key scientific sessions tell us about new directions that lie ahead?
To learn more, subscribers can sign-in.
This content is restricted to subscribers